IgM Autoantibodies Can Be Correlated in Cases of Atherosclerosis
|
By LabMedica International staff writers Posted on 20 Feb 2012 |
|
Low levels of immunoglobulin-M (IgM) autoantibodies against lipid phosphorylcholine (PC) add prognostic information in acute coronary syndromes (ACS).
The IgM autoantibodies can be easily measured by immunoassay and can be correlated with other known biomarkers in cases of atherosclerosis and other inflammatory diseases.
A team of scientists from the Karolinska Institutet (Stockholm, Sweden), collected and analyzed blood samples from 1,185 patients within 24 hours of admission between September 1995 and March 2001. Serum IgM anti-PC titers were measured by an enzyme-linked immunosorbent assay (ELISA) using a prototype of the Athera CVDefine kit. The assay is based on PCs covalently linked to bovine serum albumin coated onto 96-well microtiter plates. The detection limit was 0.5 U/L and coefficients of variation were less than 7%.
The results of the analysis showed that patients with low levels of anti-PC in connection with ACS and refractory, unstable angina run a greater risk of complications and premature death. The risk of death was more than double in coronary patients with low levels of anti-PC, who also had a significantly higher risk of additional heart attacks or other complications. The results also demonstrated for the first time that low anti-PC titers in ACS are associated with a considerably increased risk of a new acute cardiovascular event during several years, as well as increased mortality risk within, at least, the first 18 months after the primary ACS event. Low anti-PC titers may therefore represent a novel paradigm for reporting reduced atheroprotection in coronary vascular disease (CVD). The Athera CVDefine ELISA kit used in the study is a product of Athera Biotechnologies AB (Stockholm, Sweden).
Johan Frostegård, PhD, lead author and a professor at the Karolinska Institutet said, "The immunological treatment of cardiovascular diseases is clearly a Swedish specialty. Other Swedish researchers maintain that it's apolipoprotein B, an important constituent of LDL, that we should be vaccinating against, but the two aren't mutually exclusive and a combination is conceivable and something that we're now also testing." His team has spent many years developing immunological treatments for atherosclerotic plaque based on exploiting anti-PC to target phosphorylcholine. The study was published online on February 3, 2012, in the International Journal of Cardiology.
Related Links:
Karolinska Institutet
Athera Biotechnologies AB
The IgM autoantibodies can be easily measured by immunoassay and can be correlated with other known biomarkers in cases of atherosclerosis and other inflammatory diseases.
A team of scientists from the Karolinska Institutet (Stockholm, Sweden), collected and analyzed blood samples from 1,185 patients within 24 hours of admission between September 1995 and March 2001. Serum IgM anti-PC titers were measured by an enzyme-linked immunosorbent assay (ELISA) using a prototype of the Athera CVDefine kit. The assay is based on PCs covalently linked to bovine serum albumin coated onto 96-well microtiter plates. The detection limit was 0.5 U/L and coefficients of variation were less than 7%.
The results of the analysis showed that patients with low levels of anti-PC in connection with ACS and refractory, unstable angina run a greater risk of complications and premature death. The risk of death was more than double in coronary patients with low levels of anti-PC, who also had a significantly higher risk of additional heart attacks or other complications. The results also demonstrated for the first time that low anti-PC titers in ACS are associated with a considerably increased risk of a new acute cardiovascular event during several years, as well as increased mortality risk within, at least, the first 18 months after the primary ACS event. Low anti-PC titers may therefore represent a novel paradigm for reporting reduced atheroprotection in coronary vascular disease (CVD). The Athera CVDefine ELISA kit used in the study is a product of Athera Biotechnologies AB (Stockholm, Sweden).
Johan Frostegård, PhD, lead author and a professor at the Karolinska Institutet said, "The immunological treatment of cardiovascular diseases is clearly a Swedish specialty. Other Swedish researchers maintain that it's apolipoprotein B, an important constituent of LDL, that we should be vaccinating against, but the two aren't mutually exclusive and a combination is conceivable and something that we're now also testing." His team has spent many years developing immunological treatments for atherosclerotic plaque based on exploiting anti-PC to target phosphorylcholine. The study was published online on February 3, 2012, in the International Journal of Cardiology.
Related Links:
Karolinska Institutet
Athera Biotechnologies AB
Gold Member
Hematology Analyzer
Medonic M32B
Rapid Molecular Testing Device
FlashDetect Flash10
Human Estradiol Assay
Human Estradiol CLIA Kit
Latest Immunology News
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more
Molecular Diagnostics
view channel
At-Home Blood Tests Accurately Detect Key Alzheimer's Biomarkers
Diagnosing Alzheimer’s disease typically relies on brain scans or spinal fluid tests, which are invasive, costly, and difficult to access outside specialist clinics. These barriers have limited large-scale... Read more
Blood Test Combined with MRI Brain Scans Reveals Two Distinct Multiple Sclerosis Types
Multiple sclerosis (MS) affects more than 2.8 million people worldwide, yet predicting how the disease will progress in individual patients remains difficult. Current MS classifications are based on clinical... Read more
Ultra-Sensitive Blood Biomarkers Enable Population-Scale Insights into Alzheimer’s Pathology
Accurately estimating how many people carry Alzheimer’s disease pathology has long been a challenge, as traditional methods rely on small, clinic-based samples rather than the general population.... Read more
Blood Test Could Predict Death Risk in World’s Most Common Inherited Heart Disease
Hypertrophic cardiomyopathy (HCM) is the world’s most common inherited heart condition and affects millions of people globally. While some patients live with few or no symptoms, others develop heart failure,... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreMicrobiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Pathology
view channel
ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
Urine drug testing plays a critical role in the emergency department, particularly for patients presenting with suspected overdose or altered mental status. Accurate and timely results can directly influence... Read more
New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
Ovarian cancer affects around one in 50 women during their lifetime, with roughly 7,000 diagnoses each year in the UK. The disease is often detected late because symptoms such as bloating, abdominal pain,... Read more
Technology
view channel
Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
Detecting cancer early and tracking how it responds to treatment remains a major challenge, particularly when cancer cells are present in extremely low numbers in the bloodstream. Circulating tumor cells... Read more
AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read more
Industry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more
